Application of camelid heavy-chain variable domains (VHHs) in prevention and treatment of bacterial and viral infections

References

• Padlan EA. Anatomy of the antibody molecule. Mol Immunol. 1994;31:169–217.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occuring antibodies devoid of light chains. Nature. 1993;363:446–448.
   PubMed Web of Science ®Google Scholar
• Muyldermans S, Atarhouch T, Saldanha J, et al. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 1994;7:1129–1135.
   PubMedGoogle Scholar
• Harmsen MM, Ruuls RC, Nijman IJ, et al. Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol Immunol. 2000;37:579–590.
   PubMed Web of Science ®Google Scholar
• Vu KB, Arbabi Ghahroudi M, Wyns L, et al. Comparison of Llama VH Sequences from Conventional and Heavy Chain Antibodies. Mol Immunol. 1997;34:1121–1131.
   PubMed Web of Science ®Google Scholar
• Sheriff S, Constantine KL. Redefining the minimal antigen-binding fragment. Nat Struct Biol. 1996;3:733–736.
   PubMedGoogle Scholar
• Zhang J, Tanha J, Hirama T, et al. Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. J Mol Biol. 2004;335:49–56.
   PubMed Web of Science ®Google Scholar
• Chothia C, Gelfand I, Kister A. Structural determinants of immunoglobulin variable domain. J Mol Biol. 1998;278:457–479.
   PubMed Web of Science ®Google Scholar
• Desmyter A, Transue TR, Ghahroudi MA, et al. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat Struct Biol. 1996;3:803–811.
   PubMedGoogle Scholar
• Desmyter A, Decanniere K, Muyldermans S, et al. Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-domain Antibody. J Biol Chem. 2001;276:26285–26290.
   PubMed Web of Science ®Google Scholar
• Arbabi Ghahroudi M, Desmyter A, Wyns L, et al. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 1997;414:521–526.
   PubMed Web of Science ®Google Scholar
• Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol. 2007;77:13–22.
   PubMed Web of Science ®Google Scholar
• Qi H, Lu H, Qiu H-J, et al. Phagemid Vectors for Phage Display: Properties, Characteristics and Construction. J Mol Biol. 2012;417:129–143.
   PubMed Web of Science ®Google Scholar
• Rondof S, Koch J, Breitling F, et al. A helper phage to improve single-chain antibody presentation in phage display. Nat Biotechnol. 2001;19:75–78.
   PubMed Web of Science ®Google Scholar
• Frenken LGJ, Van Der Linden RHJ, Hermans PWJJ, et al. Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol. 2000;78:11–21.
   PubMed Web of Science ®Google Scholar
• Rahbarizadeh F, Rasaee MJ, Forouzandeh M, et al. Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris. Mol Immunol. 2006;43:426–435.
   PubMed Web of Science ®Google Scholar
• Touger-Decker R, Van Loveren C. Sugars and dental caries. Am J Clin Nutr. 2003;78:881S–892S.
   PubMed Web of Science ®Google Scholar
• Forssten SD, Björklund M, Ouwehand AC. Streptococcus mutans, caries and simulation models. Nutrients. 2010;2:290–298.
   PubMed Web of Science ®Google Scholar
• Krüger C, Hultberg A, Marcotte H, et al. Therapeutic effect of llama derived VHH fragments against Streptococcus mutans on the development of dental caries. Appl Microbiol Biotechnol. 2006;72:732–737.
   PubMed Web of Science ®Google Scholar
• Russell MW, Lehner T. Characterisation of antigens extracted from cells and culture fluids of Streptococcus mutans serotype c. Arch Oral Biol. 1978;23:7–15.
   PubMed Web of Science ®Google Scholar
• Szynol A, De Soet JJ, Sieben-Van Tuyl E, et al. Bactericidal Effects of a Fusion Protein of Llama Heavy-Chain Antibodies Coupled to Glucose Oxidase on Oral Bacteria. Antimicrob Agents Chemother. 2004;48:3390–3395.
   PubMed Web of Science ®Google Scholar
• Tenovuo J, Pruitt KM. Relationship of the human salivary peroxidase system to oral health. J Oral Pathol. 1984;13:573–584.
   PubMedGoogle Scholar
• Pålsson-McDermott EM, O'Neill LAJ. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology. 2004;113:153–162.
   PubMed Web of Science ®Google Scholar
• Sweet MJ, Hume DA. Endotoxin signal transduction in macrophages. J Leukoc Biol. 1996;60:8–26.
   PubMed Web of Science ®Google Scholar
• Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420:885–891.
   PubMed Web of Science ®Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal Disease. N Engl J Med. 2001;344:1378–1388.
   PubMed Web of Science ®Google Scholar
• Scholten RJ, Kuipers B, Valkenburg HA, et al. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J Med Microbiol. 1994;41:236–243.
   PubMed Web of Science ®Google Scholar
• Tsai CM, Boykins R, Frasch CE. Heterogeneity and variation among Neisseria meningitidis lipopolysaccharides. J Bacteriol. 1983;155:498–504.
   PubMed Web of Science ®Google Scholar
• Pollack M, Raubitschek AA, Larrick JW. Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides. J Clin Invest. 1987;79:1421–1430.
   PubMed Web of Science ®Google Scholar
• Di Padova FE, Brade H, Barclay GR, et al. A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect Immun. 1993;61:3863–3872.
   PubMed Web of Science ®Google Scholar
• El Khattabi M, Adams H, Heezius E, et al. Llama Single-Chain Antibody That Blocks Lipopolysaccharide Binding and Signaling: Prospects for Therapeutic Applications. Clin. Vaccine Immunol. 2006;13:1079–1086.
   PubMed Web of Science ®Google Scholar
• Berberov EM, Zhou Y, Francis DH, et al. Relative importance of heat-labile enterotoxin in the causation of severe diarrheal disease in the gnotobiotic piglet model by a strain of enterotoxigenic Escherichia coli that produces multiple enterotoxins. Infect Immun. 2004;72:3914–3924.
   PubMed Web of Science ®Google Scholar
• Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev. 1998;11:142–201.
   PubMed Web of Science ®Google Scholar
• Nair B, Takeda Y. The heat-stable enterotoxins. Microb Pathog. 1998;24:123–131.
   PubMed Web of Science ®Google Scholar
• Van den Broeck W, Cox E, Oudega B, et al. The F4 fimbrial antigen of Escherichia coli and its receptors. Vet Microbiol. 2000;71:223–244.
   PubMed Web of Science ®Google Scholar
• Tzipori S, Chandler D, Smith M, et al. Factors contributing to postweaning diarrhoea in a large intensive piggery. Aust Vet J. 1980;56:274–278.
   PubMedGoogle Scholar
• Osek J. Detection of the enteroaggregative Escherichia coli heat-stable enterotoxin 1 (EAST1) gene and its relationship with fimbrial and enterotoxin markers in E. coli isolates from pigs with diarrhoea. Vet Microbiol. 2003;91:65–72.
   PubMed Web of Science ®Google Scholar
• Harmsen MM, Van Solt CB, Hoogendoorn A, et al. Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea. Vet Microbiol. 2005;111:89–98.
   PubMed Web of Science ®Google Scholar
• Macasaet FF, Kidd PA, Bolano CR, et al. The etiology of acute respiratory infections. 3. The role of viruses and bacteria. J Pediatr. 1968;72:829–839.
   Google Scholar
• Backman K, Piippo-Savolainen E, Ollikainen H, et al. Adults face increased asthma risk after infant RSV bronchiolitis and reduced respiratory health-related quality of life after RSV pneumonia. Acta Paediatr. 2014;103:850–855.
   PubMed Web of Science ®Google Scholar
• Sikkel MB, Quint JK, Mallia P, et al. Respiratory Syncytial Virus Persistence in Chronic Obstructive Pulmonary Disease. Pediatr Infect Dis J. 2008;27:S63–S70.
   PubMed Web of Science ®Google Scholar
• Zhang L, Peeples ME, Boucher RC, et al. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol. 2002;76:5654–5666.
   PubMed Web of Science ®Google Scholar
• Sterner G, Wolontis S, Bloth B, et al. Respiratory syncytial virus. An outbreak of acute respiratory illnesses in a home for infants. Acta Paediatr Scand. 1966;55:273–279.
   PubMed Web of Science ®Google Scholar
• Huang YT, Wertz GW. The genome of respiratory syncytial virus is a negative-stranded RNA that codes for at least seven mRNA species. J Virol. 1982;43:150–157.
   PubMed Web of Science ®Google Scholar
• Levine S, Klaiber-Franco R, Paradiso PR. Demonstration that Glycoprotein G Is the Attachment Protein of Respiratory Syncytial Virus. J Gen Virol. 1987;68:2521–2524.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Hruska J. Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein. J Virol. 1983;47:171–177.
   PubMed Web of Science ®Google Scholar
• Techaarpornkul S, Barretto N, Peeples ME. Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J Virol. 2001;75:6825–6834.
   PubMed Web of Science ®Google Scholar
• Peret TC, Golub JA, Anderson LJ, et al. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol. 1998;79:2221–2229.
   PubMed Web of Science ®Google Scholar
• Johnson PR, Olmsted RA, Prince GA, et al. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol. 1987;61:3163–3166.
   PubMed Web of Science ®Google Scholar
• Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–537.
   Web of Science ®Google Scholar
• Detalle L, Stohr T, Palomon C, et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016;60:6–13.
   PubMed Web of Science ®Google Scholar
• Ablynx. Results from the first-in-infant Phase I/IIa study with the anti-RSV Nanobody, ALX-0171 [Internet]. ALX-0171. 2016 [cited 2016 Nov 23]. Available from: http://www.ablynx.com/uploads/data/files/ablynx_alx-0171_first-in-infantstudyresults_webcastpresentation.pdf.
   Google Scholar
• Landsteiner K, Popper E. Übertragung der Poliomyelitis acuta auf Affen. Zeitschr Immunitätsforsch. 1909;2:377–390.
   Google Scholar
• Bodian D, Morgan IM, Howe HA. Differentiation of types of poliomyelitis viruses; the grouping of 14 strains into three basic immunological types. Am J Hyg. 1949;49:234–245.
   PubMedGoogle Scholar
• Kitamura N, Semler BL, Rothberg PG, et al. Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature. 1981;291:547–553.
   PubMed Web of Science ®Google Scholar
• Maizel JV, Summers DF. Evidence for differences in size and composition of the poliovirus-specific polypeptides in infected HeLa cells. Virology. 1968;36:48–54.
   PubMed Web of Science ®Google Scholar
• Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 A resolution. Science. 1985;229:1358–1365.
   PubMed Web of Science ®Google Scholar
• Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 1989;56:855–865.
   PubMed Web of Science ®Google Scholar
• Colston E, Racaniello VR. Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor. EMBO J. 1994;13:5855–5862.
   PubMed Web of Science ®Google Scholar
• Rossmann MG. Viral cell recognition and entry. Protein Sci. 1994;3:1712–1725.
   PubMed Web of Science ®Google Scholar
• Fricks CE, Hogle JM. Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding. J Virol. 1990;64:1934–1945.
   PubMed Web of Science ®Google Scholar
• Bodian D. Emerging concept of poliomyelitis infection. Science. 1955;122:105–108.
   PubMed Web of Science ®Google Scholar
• Salk JE. Studies in Human Subjects on Active Immunization against Poliomyelitis. I. A Preliminary Report of Experiments in Progress. J Am Med Assoc. 1953;151:1081–1098.
   PubMed Web of Science ®Google Scholar
• Sabin AB. Present status of attenuated live-virus poliomyelitis vaccine. J Am Med Assoc. 1956;162:1589–1596.
   PubMed Web of Science ®Google Scholar
• Nathanson N, Kew OM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. Am J Epidemiol. 2010;172:1213–1229.
   PubMed Web of Science ®Google Scholar
• Thomas AA, Brioen P, Boeyé A. A monoclonal antibody that neutralizes poliovirus by cross-linking virions. J Virol. 1985;54:7–13.
   PubMed Web of Science ®Google Scholar
• Thys B, De Palma AM, Neyts J, et al. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond. Antiviral Res. 2008;78:278–281.
   PubMed Web of Science ®Google Scholar
• Thys B, Schotte L, Muyldermans S, et al. In vitro antiviral activity of single domain antibody fragments against poliovirus. Antiviral Res. 2010;87:257–264.
   PubMed Web of Science ®Google Scholar
• Strauss M, Schotte L, Thys B, et al. Five of Five VHHs Neutralizing Poliovirus Bind the Receptor-Binding Site. J Virol. 2016;90:3496–3505.
   PubMed Web of Science ®Google Scholar
• Schotte L, Strauss M, Thys B, et al. Mechanism of action and capsid-stabilizing properties of VHHs with an in vitro antipolioviral activity. J Virol. 2014;88:4403–4413.
   PubMed Web of Science ®Google Scholar
• Schotte L, Thys B, Strauss M, et al. Characterization of Poliovirus Neutralization Escape Mutants of Single-Domain Antibody Fragments (VHHs). Antimicrob Agents Chemother. 2015;59:4695–4706.
   PubMed Web of Science ®Google Scholar
• Seifert DB, Phillips JA. The production of monoclonal antibody in growth-arrested hybridomas cultivated in suspension and immobilized modes. Biotechnol Prog. 1999;15:655–666.
   PubMed Web of Science ®Google Scholar
• Coppieters K, Dreier T, Silence K, et al. Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 2006;54:1856–1866.
   PubMedGoogle Scholar
• Roovers RC, Laeremans T, Huang L, et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother. 2007;56:303–317.
   PubMed Web of Science ®Google Scholar
• Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011;118:757–765.
   PubMed Web of Science ®Google Scholar
• Rothbauer U, Zolghadr K, Tillib S, et al. Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat Methods. 2006;3:887–890.
   PubMed Web of Science ®Google Scholar
• Huang L, Gainkam LOT, Caveliers V, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol. 2008;10:167–175.
   PubMed Web of Science ®Google Scholar
• Hmila I, Saerens D, Ben Abderrazek R, et al. A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J. 2010;24:3479–3489.
   PubMed Web of Science ®Google Scholar
• Chavanayarn C, Thanongsaksrikul J, Thueng-in K, et al. Humanized-Single Domain Antibodies (VH/VHH) that Bound Specifically to Naja kaouthia Phospholipase A2 and Neutralized the Enzymatic Activity. Toxins. 2012;4:554–567.
   PubMed Web of Science ®Google Scholar